menu
    • menu
    [{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"CD163","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OncoResponse \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"OncoResponse \/ Regeneron"},{"orgOrder":0,"company":"OncoResponse","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"OR502","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"OncoResponse \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ CPRIT"},{"orgOrder":0,"company":"OncoResponse","sponsor":"RiverVest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"OR502","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"OncoResponse \/ RiverVest Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ RiverVest Venture Partners"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Not Applicable"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OncoResponse \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"OncoResponse \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoResponse

    Menu

    OncoResponse

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR502,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoResponse Reports OR502 Phase 1 Trial Results in Advanced Cancer

                            Details : OR502 is a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody. It is being evaluated for the treatment of advanced solid tumors.

                            Brand Name : OR502

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 07, 2024

                            Lead Product(s) : OR502,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR502,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, Anti-LILRB2 Antibody, in Subjects with...

                            Details : OR502 a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody. It is being evaluated for the treatment of advanced solid tumors.

                            Brand Name : OR502

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 29, 2023

                            Lead Product(s) : OR502,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR502

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : CPRIT

                            Deal Size : $13.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

                            Details : The CPRIT award will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.

                            Brand Name : OR502

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : OR502

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : CPRIT

                            Deal Size : $13.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR502

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : RiverVest Venture Partners

                            Deal Size : $14.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

                            Details : The investment will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.

                            Brand Name : OR502

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : OR502

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : RiverVest Venture Partners

                            Deal Size : $14.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            OncoResponse

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR2805,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo...

                            Details : The supply agreement will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder using OncoResponse’s proprietary B-cell discovery platform.

                            Brand Name : OR2805

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 07, 2022

                            Lead Product(s) : OR2805,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth